Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Achaogen Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Achaogen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Achaogen Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Achaogen Raises US$19 Million In Venture Financing 11
Licensing Agreements 12
Achaogen Enters into Licensing Agreement with Crystal Bioscience 12
Achaogen Enters into Licensing Agreement with Trianni 13
Equity Offering 14
Achaogen Raises USD112.5 Million in Public Offering of Shares 14
Achaogen to Raise USD10 Million in Private Placement of Shares 16
Achaogen Receives USD5.3 Million in Public Offering of Shares 17
Achaogen Raises USD101 Million in Public Offering of Shares 18
Achaogen Raises USD25 Million in Private Placement of Shares 20
Achaogen Completes IPO For US$82.8 Million 22
Achaogen Inc – Key Competitors 23
Achaogen Inc – Key Employees 24
Achaogen Inc – Locations And Subsidiaries 25
Head Office 25
Recent Developments 26
Financial Announcements 26
Nov 08, 2017: Achaogen Reports Third Quarter 2017 Financial Results and Provides Corporate Update 26
Aug 03, 2017: Achaogen Reports Second Quarter 2017 Financial Results and Provides Corporate Update 28
May 08, 2017: Achaogen Reports First Quarter 2017 Financial Results and Provides Corporate Update 30
Mar 14, 2017: Achaogen Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 32
Nov 07, 2016: Achaogen Reports Third Quarter 2016 Financial Results 34
Aug 08, 2016: Achaogen Reports Second Quarter 2016 Financial Results and Provides Corporate Update 35
May 05, 2016: Achaogen Reports First Quarter 2016 Financial Results 37
Mar 15, 2016: Achaogen Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update 38
Corporate Communications 40
Sep 18, 2017: Achaogen Adds Liz Bhatt as Chief Business Officer 40
Jul 13, 2017: Achaogen Appoints Dr. Karen Bernstein to its Board of Directors 41
Feb 27, 2017: Achaogen Adds Janet Dorling as Chief Commercial Officer 42
Feb 23, 2017: Achaogen Announces Leadership Promotions 43
Jan 05, 2017: Achaogen appoints new board member 44
Jun 03, 2016: Achaogen Adds Tobin Schilke as Chief Financial Officer 45
Government and Public Interest 46
May 05, 2017: Achaogen Receives Investment from the Bill & Melinda Gates Foundation to Develop Antibodies Against Gram-Negative Bacteria 46
Product News 47
07/25/2017: Achaogen Wins CARB-X Funding Award to Advance Development of LpxC Inhibitor Antibiotic to Fight Drug Resistant Infections 47
07/15/2016: Achaogen to Host Key Opinion Leader Meeting on Multi-Drug Resistant Infections on July 19, 2016 in New York 48
06/20/2016: Achaogen Plazomicin Highlighted in Multiple Presentations at ASM Microbe 2016 Outlining Bactericidal Activity Against MDR Pathogens 49
06/09/2016: Achaogen Announces Plazomicin Data Presentations at ASM Microbe 2016 Annual Meeting 51
Mar 01, 2017: Achaogen Highlights Emerging Pipeline of Antibacterials Including a new Orally-Administered Antibiotic Clinical Candidate at Company’s R&D Day 52
Clinical Trials 53
Jun 01, 2017: Achaogen Initiates C-Scape Clinical Development Program with Phase 1 Study of Orally-Administered Antibacterial Candidate 53
Sep 01, 2016: Achaogen Completes Patient Enrollment in Phase 3 EPIC Clinical Trial of Plazomicin 54
Jun 02, 2016: Achaogen Reaches 50 Percent Patient Enrollment in Phase 3 EPIC Registration Trial of Plazomicin 55
Apr 05, 2016: Achaogen Announces Acceleration of Expected Timeline for Reporting Top-Line Results from Phase 3 EPIC Registration Clinical Trial of Plazomicin 56
Jan 11, 2016: Achaogen Announces Enrollment of First Patient in EPIC, a Phase 3 Clinical Trial for the Treatment of Complicated Urinary Tract Infections With Plazomicin 57
Appendix 58
Methodology 58
About GlobalData 58
Contact Us 58
Disclaimer 58
Achaogen Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Achaogen Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Achaogen Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Achaogen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Achaogen Raises US$19 Million In Venture Financing 11
Achaogen Enters into Licensing Agreement with Crystal Bioscience 12
Achaogen Enters into Licensing Agreement with Trianni 13
Achaogen Raises USD112.5 Million in Public Offering of Shares 14
Achaogen to Raise USD10 Million in Private Placement of Shares 16
Achaogen Receives USD5.3 Million in Public Offering of Shares 17
Achaogen Raises USD101 Million in Public Offering of Shares 18
Achaogen Raises USD25 Million in Private Placement of Shares 20
Achaogen Completes IPO For US$82.8 Million 22
Achaogen Inc, Key Competitors 23
Achaogen Inc, Key Employees 24